An experimental acne drug just failed two key clinical trials — and the stock's getting obliterated

pulse

March 5, 2018 2:57 PM

Dermatology biotech Dermira said on Monday that its experimental drug to treat acne failed two key clinical trials.

Dermatology biotech
Dermira was studying the drug in kids over 9 years old to see if it could reduce the number of inflammatory and non-inflammatory lesions on that person's skin compared to a control arm.
Dermira, which had a market cap of about $1 billion when markets closed on Friday was down as much as 64% on Monday in pre-market trading.
"We are surprised and extremely disappointed by the results of the Phase 3 program," Dermira CEO Tom Wiggans said in a news release.
The company is also developing treatments for hyperhidrosis, otherwise known as excessive sweating, and atopic dermatitis.

pulse

Enhance Your Pulse News Experience!

Get rewards worth up to $20 when selected to participate in our exclusive focus group. Your input will help us to make informed decisions that align with your needs and preferences.

I've got feedback!

JOIN OUR PULSE COMMUNITY!

Unblock notifications in browser settings.

Eyewitness? Submit your stories now via social or:

Email: eyewitness@pulse.ng